| Bioactivity | Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study [1][2]. |
| Name | Benralizumab (anti-IL5RA ) |
| CAS | 1044511-01-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019;5(3):00009-2019. Published 2019 Sep 25. [2]. Kolbeck R, et al. MEDI-563, a humanized anti-IL-5receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicityfunction. J Allergy Clin Immunol. 2010;125(6):1344-1353.e2. |